S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
Average 126% gains – NO losers!?   (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
The Safest Option in Trades! (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
Average 126% gains – NO losers!?   (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
The Safest Option in Trades! (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
Average 126% gains – NO losers!?   (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
The Safest Option in Trades! (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
The 2 Dow Stocks with Decade-Long Win Streaks on the Line
3 Stable Growth Stocks for Bumpy Times
Average 126% gains – NO losers!?   (Ad)pixel
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
The Safest Option in Trades! (Ad)pixel
NYSE:BMY

Bristol-Myers Squibb - BMY Stock Forecast, Price & News

$74.46
-0.40 (-0.53%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$74.28
$75.52
50-Day Range
$72.12
$79.98
52-Week Range
$53.22
$80.59
Volume
5.82 million shs
Average Volume
13.72 million shs
Market Capitalization
$158.99 billion
P/E Ratio
24.74
Dividend Yield
2.89%
Price Target
$75.57

Bristol-Myers Squibb MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1.5% Upside
$75.57 Price Target
Short Interest
Healthy
1.31% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.30
Upright™ Environmental Score
News Sentiment
0.02mentions of Bristol-Myers Squibb in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$7.09 M Sold Last Quarter
Proj. Earnings Growth
7.44%
From $7.53 to $8.09 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.83 out of 5 stars

Medical Sector

72nd out of 1,112 stocks

Pharmaceutical Preparations Industry

21st out of 544 stocks

BMY stock logo

About Bristol-Myers Squibb (NYSE:BMY) Stock

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Bristol-Myers Squibb Stock Down 0.5 %

Bristol-Myers Squibb stock opened at $74.46 on Friday. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.44 and a quick ratio of 1.34. The stock has a market capitalization of $158.99 billion, a price-to-earnings ratio of 24.70, a PEG ratio of 1.59 and a beta of 0.40. Bristol-Myers Squibb has a 1-year low of $53.22 and a 1-year high of $80.59. The business has a fifty day moving average price of $74.94 and a 200-day moving average price of $73.00.

Bristol-Myers Squibb (NYSE:BMY - Get Rating) last posted its quarterly earnings data on Wednesday, July 27th. The biopharmaceutical company reported $1.93 earnings per share for the quarter, topping analysts' consensus estimates of $1.79 by $0.14. The firm had revenue of $11.89 billion during the quarter, compared to analysts' expectations of $11.50 billion. Bristol-Myers Squibb had a return on equity of 49.31% and a net margin of 14.04%. The business's quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.93 EPS. Equities research analysts forecast that Bristol-Myers Squibb will post 7.53 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 1st. Shareholders of record on Friday, July 1st were given a dividend of $0.54 per share. The ex-dividend date of this dividend was Thursday, June 30th. This represents a $2.16 dividend on an annualized basis and a yield of 2.90%. Bristol-Myers Squibb's dividend payout ratio is currently 71.76%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Atlantic Securities raised their target price on Bristol-Myers Squibb from $82.00 to $83.00 and gave the company an "overweight" rating in a research report on Thursday, July 28th. BMO Capital Markets raised their price objective on Bristol-Myers Squibb from $87.00 to $92.00 in a report on Monday, May 2nd. Bank of America boosted their target price on Bristol-Myers Squibb from $78.00 to $80.00 and gave the company a "buy" rating in a research note on Monday, June 6th. Guggenheim lifted their price target on Bristol-Myers Squibb from $72.00 to $80.00 in a research report on Monday, May 2nd. Finally, Truist Financial boosted their target price on Bristol-Myers Squibb from $76.00 to $81.00 in a report on Monday, May 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $75.57.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 30,000 shares of Bristol-Myers Squibb stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $74.04, for a total transaction of $2,221,200.00. Following the completion of the sale, the chief executive officer now owns 551,104 shares of the company's stock, valued at approximately $40,803,740.16. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 30,000 shares of Bristol-Myers Squibb stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $74.04, for a total transaction of $2,221,200.00. Following the completion of the sale, the chief executive officer now owns 551,104 shares of the company's stock, valued at approximately $40,803,740.16. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Sandra Leung sold 65,000 shares of Bristol-Myers Squibb stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $74.89, for a total value of $4,867,850.00. Following the sale, the executive vice president now directly owns 308,627 shares of the company's stock, valued at approximately $23,113,076.03. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by insiders.

Receive BMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bristol-Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.

BMY Stock News Headlines

Get These 3 Juicy Dividend Yields While They Last (BMY)
A good strategy for this unprecedented backdrop may be to bunker down with steady dividend paying companies that are likely to trend higher as market conditions improve. Compared to what was available at the market peak, there are certainly some big dividend yields out there.
What's Next For Bristol Myers Squibb Stock?
2 Stocks That Could Lead the Market Recovery
Today's Cell Therapy Insights Shaping Tomorrow
Bristol-Myers Squibb: Nowhere To Go Even After Q2
C2C4C: Back on the Road and Bigger Than Ever
Bristol-Myers Squibb (NYSE:BMY) PT Raised to $83.00
See More Headlines
Receive BMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bristol-Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.

BMY Company Calendar

Ex-Dividend for 8/1 Dividend
6/30/2022
Last Earnings
7/27/2022
Dividend Payable
8/01/2022
Today
8/11/2022
Next Earnings (Estimated)
10/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
11012210
Employees
32,200
Year Founded
1887

Price Target and Rating

Average Stock Price Forecast
$75.57
High Stock Price Forecast
$92.00
Low Stock Price Forecast
$49.00
Forecasted Upside/Downside
+1.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

Net Income
$6.99 billion
Pretax Margin
16.25%

Debt

Sales & Book Value

Annual Sales
$46.39 billion
Cash Flow
$12.33 per share
Book Value
$15.30 per share

Miscellaneous

Outstanding Shares
2,135,255,000
Free Float
2,133,333,000
Market Cap
$158.99 billion
Optionable
Optionable
Beta
0.40

Social Links















BMY Stock - Frequently Asked Questions

Should I buy or sell Bristol-Myers Squibb stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BMY shares.
View BMY analyst ratings
or view top-rated stocks.

What is Bristol-Myers Squibb's stock price forecast for 2022?

12 Wall Street analysts have issued twelve-month price targets for Bristol-Myers Squibb's stock. Their BMY share price forecasts range from $49.00 to $92.00. On average, they expect the company's share price to reach $75.57 in the next year. This suggests a possible upside of 1.5% from the stock's current price.
View analysts price targets for BMY
or view top-rated stocks among Wall Street analysts.

How have BMY shares performed in 2022?

Bristol-Myers Squibb's stock was trading at $62.35 on January 1st, 2022. Since then, BMY shares have increased by 19.4% and is now trading at $74.46.
View the best growth stocks for 2022 here
.

Are investors shorting Bristol-Myers Squibb?

Bristol-Myers Squibb saw a drop in short interest in the month of July. As of July 15th, there was short interest totaling 27,330,000 shares, a drop of 29.9% from the June 30th total of 38,980,000 shares. Based on an average trading volume of 13,450,000 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.3% of the company's shares are sold short.
View Bristol-Myers Squibb's Short Interest
.

When is Bristol-Myers Squibb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our BMY earnings forecast
.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb (NYSE:BMY) released its earnings results on Wednesday, July, 27th. The biopharmaceutical company reported $1.93 earnings per share for the quarter, topping analysts' consensus estimates of $1.79 by $0.14. The biopharmaceutical company had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.50 billion. Bristol-Myers Squibb had a trailing twelve-month return on equity of 49.31% and a net margin of 14.04%. The business's revenue was up 1.6% on a year-over-year basis. During the same period last year, the business posted $1.93 EPS.
Read the conference call transcript
.

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb declared a quarterly dividend on Thursday, June 16th. Investors of record on Friday, July 1st will be given a dividend of $0.54 per share on Monday, August 1st. This represents a $2.16 annualized dividend and a dividend yield of 2.90%. The ex-dividend date of this dividend is Thursday, June 30th.
Read our dividend analysis for BMY
.

Is Bristol-Myers Squibb a good dividend stock?

Bristol-Myers Squibb (NYSE:BMY) pays an annual dividend of $2.16 per share and currently has a dividend yield of 2.89%. The company has been increasing its dividend for 16 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 71.76%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, BMY will have a dividend payout ratio of 26.70% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for BMY.

When did Bristol-Myers Squibb's stock split?

Bristol-Myers Squibb's stock split before market open on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were payable to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of $7.44-$7.74 for the period, compared to the consensus EPS estimate of $7.46. The company issued revenue guidance of $46.00 billion-$46.00 billion, compared to the consensus revenue estimate of $46.24 billion.

What is Giovanni Caforio's approval rating as Bristol-Myers Squibb's CEO?

659 employees have rated Bristol-Myers Squibb Chief Executive Officer Giovanni Caforio on Glassdoor.com. Giovanni Caforio has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Bristol-Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), NVIDIA (NVDA), CVS Health (CVS), Cisco Systems (CSCO) and Bank of America (BAC).

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (1.04%), Deutsche Bank AG (0.85%), California Public Employees Retirement System (0.53%), Swiss National Bank (0.44%), Sumitomo Mitsui Trust Holdings Inc. (0.33%) and Pzena Investment Management LLC (0.20%). Insiders that own company stock include Adam Dubow, Autenried Paul Von, Christopher S Boerner, David V Elkins, Dinesh C Paliwal, Giovanni Caforio, John E Elicker, Joseph Eid, Karen Murphy Santiago, Louis S Schmukler, Rupert Vessey, Sandra Leung and Terrie Curran.
View institutional ownership trends
.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $74.46.

How much money does Bristol-Myers Squibb make?

Bristol-Myers Squibb (NYSE:BMY) has a market capitalization of $158.99 billion and generates $46.39 billion in revenue each year. The biopharmaceutical company earns $6.99 billion in net income (profit) each year or $3.01 on an earnings per share basis.

How many employees does Bristol-Myers Squibb have?

The company employs 32,200 workers across the globe.

Does Bristol-Myers Squibb have any subsidiaries?

The following companies are subsidiares of Bristol-Myers Squibb: 1096271 B.C. ULC, 345 Park LLC, A.G. Medical Services P.A., AHI Investment LLC, AbVitro LLC, Abraxis BioScience Australia Pty Ltd., Abraxis BioScience Inc., Abraxis BioScience International Holding Company Inc., Abraxis BioScience LLC, Abraxis BioScience Puerto Rico LLC, Acetylon Pharmaceuticals Inc., Adnexus, Adnexus a Bristol-Myers Squibb R&D Company, Allard Labs Acquisition G.P., Amira Pharmaceuticals, Amira Pharmaceuticals Inc., Amylin Pharmaceuticals, Apothecon LLC, B-MS Generx Unlimited Company, BMS Benelux Holdings B.V., BMS Bermuda Nominees L.L.C., BMS Data Acquisition Company LLC, BMS Forex Company, BMS Holdings Sarl, BMS Holdings Spain S.L., BMS International Insurance Designated Activity Company, BMS Investco SAS, BMS Korea Holdings L.L.C., BMS Latin American Nominees L.L.C., BMS Luxembourg Partners L.L.C., BMS Omega Bermuda Holdings Finance Ltd., BMS Pharmaceutical Korea Limited, BMS Pharmaceuticals Germany Holdings B.V., BMS Pharmaceuticals International Holdings Netherlands B.V., BMS Pharmaceuticals Korea Holdings B.V., BMS Pharmaceuticals Mexico Holdings B.V., BMS Pharmaceuticals Netherlands Holdings B.V., BMS Real Estate LLC, BMS Spain Investments LLC, BMS Strategic Portfolio Investments Holdings Inc., Blisa Acquisition G.P., Bristol (Iran) S.A., Bristol Iran Private Company Limited, Bristol Laboratories Inc., Bristol Laboratories International S.A., Bristol Laboratories Medical Information Systems Inc., Bristol-Myers (Andes) L.L.C., Bristol-Myers (Private) Limited, Bristol-Myers Middle East S.A.L., Bristol-Myers Overseas Corporation, Bristol-Myers Squibb (China) Investment Co. Ltd., Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd., Bristol-Myers Squibb (Israel) Ltd., Bristol-Myers Squibb (NZ) Limited, Bristol-Myers Squibb (Proprietary) Limited, Bristol-Myers Squibb (Shanghai) Trading Co. Ltd., Bristol-Myers Squibb (Singapore) Pte. Limited, Bristol-Myers Squibb (Taiwan) Ltd., Bristol-Myers Squibb (West Indies) Ltd., Bristol-Myers Squibb A.E., Bristol-Myers Squibb Aktiebolag, Bristol-Myers Squibb Argentina S. R. L., Bristol-Myers Squibb Australia Pty. Ltd., Bristol-Myers Squibb Axia Limited, Bristol-Myers Squibb B.V., Bristol-Myers Squibb Belgium S.A., Bristol-Myers Squibb Business Services Limited, Bristol-Myers Squibb Canada Co., Bristol-Myers Squibb Canada International Limited, Bristol-Myers Squibb Delta Company Limited, Bristol-Myers Squibb Denmark Filial of Bristol-Myers Squibb AB, Bristol-Myers Squibb EMEA Sarl, Bristol-Myers Squibb Egypt LLC, Bristol-Myers Squibb Epsilon Holdings Unlimited Company, Bristol-Myers Squibb Farmaceutica Ltda., Bristol-Myers Squibb Farmaceutica Portuguesa S.A., Bristol-Myers Squibb GesmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Bristol-Myers Squibb Holding Germany GmbH & Co. KG, Bristol-Myers Squibb Holdings 2002 Limited, Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH, Bristol-Myers Squibb Holdings Ireland Unlimited Company, Bristol-Myers Squibb Holdings Limited, Bristol-Myers Squibb Holdings Pharma Ltd. Liability Company, Bristol-Myers Squibb Ilaclari Inc., Bristol-Myers Squibb India Pvt. Limited, Bristol-Myers Squibb International Company Unlimited Company, Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb Investco L.L.C., Bristol-Myers Squibb K.K., Bristol-Myers Squibb Kft., Bristol-Myers Squibb Luxembourg International S.C.A., Bristol-Myers Squibb Luxembourg S.a.r.l., Bristol-Myers Squibb MEA GmbH, Bristol-Myers Squibb Manufacturing Company, Bristol-Myers Squibb Marketing Services S.R.L., Bristol-Myers Squibb Middle East & Africa FZ-LLC, Bristol-Myers Squibb Norway Ltd., Bristol-Myers Squibb Nutricionales de Mexico S. de R.L. de C.V., Bristol-Myers Squibb Peru S.A., Bristol-Myers Squibb Pharma (HK) Ltd, Bristol-Myers Squibb Pharma (Thailand) Limited, Bristol-Myers Squibb Pharma Company, Bristol-Myers Squibb Pharma EEIG, Bristol-Myers Squibb Pharma Holding Company LLC, Bristol-Myers Squibb Pharma Ventures Corporation, Bristol-Myers Squibb Pharmaceuticals Limited, Bristol-Myers Squibb Pharmaceuticals Unlimited Company, Bristol-Myers Squibb Polska Sp. z o.o., Bristol-Myers Squibb Products SA, Bristol-Myers Squibb Puerto Rico Inc., Bristol-Myers Squibb Puerto Rico/Sanofi Pharmaceutical Partnership Puerto Rico, Bristol-Myers Squibb Romania S.R.L., Bristol-Myers Squibb S.A.U., Bristol-Myers Squibb S.r.l., Bristol-Myers Squibb SA, Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Bristol-Myers Squibb Sarl, Bristol-Myers Squibb Service Ltd., Bristol-Myers Squibb Services Sp. z o.o., Bristol-Myers Squibb Spol. s r.o., Bristol-Myers Squibb Theta Finance Ltd., Bristol-Myers Squibb Trustees Limited, Bristol-Myers Squibb Verwaltungs GmbH, Bristol-Myers Squibb de Colombia S.A., Bristol-Myers Squibb de Costa Rica Sociedad Anonima, Bristol-Myers Squibb de Guatemala S.A., Bristol-Myers Squibb de Mexico S. de R.L. de C.V., Bristol-Myers Squibb/Astrazeneca EEIG, Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Bristol-Myers de Venezuela S.C.A., CHT I LLC, CHT II LLC, CHT III LLC, CHT IV LLC, CR Finance Company LLC, Cardioxyl Pharmaceuticals, Cardioxyl Pharmaceuticals Inc., Celem LLC, Celem Ltd., Celgene, Celgene A.B., Celgene AS, Celgene Ab (Finland), Celgene Alpine Investment Co. II LLC, Celgene Alpine Investment Co. III LLC, Celgene Alpine Investment Co. LLC, Celgene ApS, Celgene B.V., Celgene BVBA, Celgene Brasil Produtos Farmacêuticos Ltda., Celgene CAR LLC, Celgene CAR Ltd., Celgene Chemicals Sarl, Celgene China Holdings LLC, Celgene Co., Celgene Corporation, Celgene Distribution B.V., Celgene EngMab GmbH, Celgene Europe B.V., Celgene Europe Limited, Celgene European Investment Company LLC, Celgene Financing Company LLC, Celgene Global Holdings Sarl, Celgene GmbH [Austria], Celgene GmbH [Germany], Celgene GmbH [Switzerland], Celgene Holdings East Corporation, Celgene Holdings II Sarl, Celgene Holdings III Sarl, Celgene Ilaç Pazarlama ve Ticaret Limited Şirketi, Celgene Inc., Celgene International Holdings Corporation, Celgene International II Sàrl, Celgene International III Sàrl, Celgene International Inc., Celgene International Sàrl, Celgene K.K., Celgene Kft., Celgene Limited [Hong Kong], Celgene Limited [Ireland], Celgene Limited [New Zealand], Celgene Limited [Taiwan], Celgene Limited [UK], Celgene Logistics Sàrl, Celgene Ltd, Celgene Luxembourg Sarl, Celgene Management Sàrl, Celgene NJ Investment Co, Celgene Netherlands B.V., Celgene Netherlands Investment B.V., Celgene Pharmaceutical (Shanghai) Co. Ltd., Celgene Pte. Ltd., Celgene Pty Ltd, Celgene Puerto Rico Distribution LLC, Celgene Quanticel Research Inc, Celgene R&D Sàrl, Celgene RIVOT LLC, Celgene RIVOT Ltd., Celgene RIVOT SRL, Celgene Receptos Limited, Celgene Receptos Sàrl, Celgene Research Incubator At Summit West LLC, Celgene Research S.L.U., Celgene Research and Development Company LLC, Celgene Research and Development I ULC, Celgene Research and Development II LLC, Celgene Research and Investment Company II LLC, Celgene S. de R.L. de C.V., Celgene S.L.U., Celgene S.R.L., Celgene SAS, Celgene Sarl AU, Celgene Sdn Bhd, Celgene Services Sàrl, Celgene Sociedade Unipessoal Lda, Celgene Sp. Z.o.o., Celgene Sro [Czech Republic], Celgene Summit Investment Co, Celgene Switzerland Holding Sarl, Celgene Switzerland II LLC, Celgene Switzerland Investment Sarl, Celgene Switzerland LLC, Celgene Switzerland Sarl, Celgene Tri A Holdings Ltd., Celgene Tri Sarl, Celgene UK Distribution Limited, Celgene UK Holdings Limited, Celgene UK Manufacturing II Limited, Celgene UK Manufacturing III Limited, Celgene UK Manufacturing Limited, Celgene d.o.o., Celgene sro [Slovakia], Celmed LLC, Celmed Ltd., ConvaTec Divestiture, Cormorant Pharmaceuticals, Cormorant Pharmaceuticals AB, Crosp Ltd., Delinia Inc., Deuteria Pharmaceuticals Inc., DuPont Pharmaceuticals, E. R. Squibb & Sons Inter-American Corporation, E. R. Squibb & Sons L.L.C., E. R. Squibb & Sons Limited, EWI Corporation, EngMab Sarl, F-star Alpha, FermaVir Pharmaceuticals L.L.C., FermaVir Research L.L.C., Flexus Biosciences, Flexus Biosciences Inc., Forbius, Galecto Biotech, GenPharm International L.L.C., Gloucester Pharmaceuticals LLC, Grove Insurance Company Ltd., Heyden Farmaceutica Portuguesa Limitada, IFM Therapeutics, Impact Biomedicines Inc., Inhibitex, Inhibitex L.L.C., Innate Tumor Immunity Inc., JuMP Holdings LLC, Juno Therapeutics GmbH, Juno Therapeutics Inc., Kosan Biosciences, Kosan Biosciences Incorporated, Linson Investments Limited, Mead Johnson (Manufacturing) Jamaica Limited, Mead Johnson Jamaica Ltd., Medarex, Morris Avenue Investment II LLC, Morris Avenue Investment LLC, MyoKardia, O.o.o. Bristol-Myers Squibb, Oy Bristol-Myers Squibb (Finland) AB, Padlock Therapeutics, Padlock Therapeutics Inc., Pharmion LLC, Princeton Pharmaceutical Products Inc., Receptos LLC, Receptos Services LLC, RedoxTherapies Inc., Route 22 Real Estate Holding Corporation, SPV A Holdings ULC, Seamair Insurance DAC, Signal Pharmaceuticals LLC, Sino-American Shanghai Squibb Pharmaceuticals Limited, Societe Francaise de Complements Alimentaires(S.O.F.C.A.), Squibb Middle East S.A., Summit West Celgene LLC, Swords Laboratories, VentiRx Pharmaceuticals Inc., Westwood-Intrafin SA, Westwood-Squibb Pharmaceuticals Inc., X-Body Inc., ZymoGenetics, ZymoGenetics Inc., ZymoGenetics LLC, ZymoGenetics Paymaster LLC, iPierian, and iPierian Inc..
Read More

When was Bristol-Myers Squibb founded?

Bristol-Myers Squibb was founded in 1887.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The official website for the company is www.bms.com. The biopharmaceutical company can be reached via phone at (212) 546-4000, via email at john.elicker@bms.com, or via fax at 212-546-4020.

This page (NYSE:BMY) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.